Escolar Documentos
Profissional Documentos
Cultura Documentos
Revisado 1.3.2021
ou
- Colecalciferol (2000UI) - 1 cápsula via oral, após o café da manhã ou Colecalciferol gotas 400U/gota ou
500U/gota - Prescrever 5- 6 gotas por dia → Internação em enfermaria
- Colecalciferol gotas 400U/gota ou 500U/gota - Prescrever 14-17 gotas por dia → Internação em UTI
● Clcr> 30
- Enoxaparina
- Até 80 Kg - 40 mg SC/ dia
Todos os pacientes internados devem
- > 80 Kg < 100 Kg- 60 Mg SC/dia
estar com anticoagulação profilática - > 100 Kg - 80 Mg SC/dia
se:
- Plaquetas > 30.000 ● Clcr < 30
- Ausência de sinais de sangramentos ativos - Heparina Não Fracionada (5.000 UI 8/8
horas - SC)
OU - CL DE CREATININA < 30
HEPARINA NÃO FRACIONADA - 12.500 UI DILUÍDO EM SF0,9% 247 Ml
- TEV CONFIRMADO CONTROLE TTPA CADA 6 HORAS E MANEJO DA INFUSÃO DE ACORDO COM TABELA ANEXA
46 - 70 Seg 0 0 MANTER
-Reconciliação medicamentosa
SIM NÃO
ACOMPANHAMENTO TELETRIAGEM /
AMBULATORIAL E
IMOBILIDADE
HISTÓRIA FAMILIAR
TROMBOFILIA
OBESIDADE
FATORES DE RISCO PARA FENÔMENOS EMBÓLICOS TROMBOSE PRÉVIA
TERAPIAS HORMONAIS
CÂNCER
INFECÇÃO ASSOCIADA
SIM NÃO
Gonçalves TJM, Gonçalves SEAB, Guarnieri A, Risegato RC, Guimarães MP, de Freitas DC, et al. Association Between Low Zinc
Levels and Severity of Acute Respiratory Distress Syndrome by New Coronavirus (SARS-CoV-2). Nutr Clin Pract. 2020 Dec
23:77-83
Caccialanza R, Laviano A, Lobascio F, Montagna E, Bruno R, Ludovisi S, et al. Early nutritional supplementation in non-critically ill
patients hospitalized for the 2019 novel coronavirus disease (COVID-19): Rationale and feasibility of a shared pragmatic protocol.
Nutrition. 2020 Jun;74:110835
Ning Tang Huan Bai Xing Chen Jiale Gong Dengju Li Ziyong Sun
First published:27 March 2020 https://doi.org/10.1111/jth.14817 1. Gunnarsson OS, Sawyer WT, Montague D, et al. Appropriate use of heparin.
Empiric vs nomogram- based dosing. Arch Intern Med 1995 Mar 13;155(5): 526-532. 2. Raschke RA, Reilly BM, Guidry JR, Fontana JR. The weight-
based heparin dosing nomogram comparde with a "standard care" nomogram. A randomized controlled trial. Ann Intern Med 1993;119(9):874-881. 3.
Rivey MP, Peterson JP. Pharmacy- managed, weight- based heparin protocol. Am J Hosp Pharm 1993 Feb;50(2):279-284. 4. Mungall D, Lord M,
Cason S, Treadwell P, Willians D, Tedrick. Developing and testing a system to improve the quality of heparin anticoagulation in patients with acute
cardiac syndromes. Am J Cardiol 1998;82(5):574-579. Novembro - 2009 5. Cory Toth and Chris Voll. Validation of a Weight-Based Nomogram for the
Use of Intravenous Heparin in Transient Ischemic Attack or Stroke. Stroke 2002;33(3): 670-674. 6. Laffan M.A.and Brads ham A.E. Laboratory
control of anticoagulant, thrombolytic and anti - platelet Therapy. In; Pratical Haematology, Dacie Jv and Lewis SM. 8 ed; cap. 19:367-380, 1995. 7.
Gerlach, AT, Pickworth, KK, Seth, SK, et al. Enoxaparin and Bleeding Complications: A Review in Patients With and Without Renal Insufficiency.
Pharmacotherapy 2000;20:771. 8. Hirsh J, Guyatt G, Albers GW, Harrington R, Schünemann HJ. Antithrombotic and thrombolytic therapy 8th Ed.
ACCP Guidelines. Chest 2008;133:71S-105S. 9. Rosborough T K. Comparison of anti-factor Xa heparin activity anda activated partial thromboplastin
time in 2,773 plasma samples from unfractionated heparin-treated patients.am J Clin Pathol.1997;108:662-668
Ministério da Saúde 2017. Protocolo de Manejo Clínico de Síndrome Respiratória Aguda Grave. Ministério da Saúde 2010. American Heart
Association, 2015
Liao X, Wang B, et al. Novel coronavirus infection during the 2019-2020 epidemic: preparing intensive care units - the experience in Sichuan
Province, China. Intensive Care Med. 2020 Higgs A, et al. Guidelines for the management of tracheal intubation in critically ill adults. British Journal
of Anaesthesia. 2017. Yang X, Yu, Y, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a
single-centered, retrospective, observational study.
Lancet Respiratory Medicine. Feb. 2020 Xie et al. Critical care crisis and some recommendations during the COVID-19 epidemic in China. Intensive
Care Med. 2020 Ross W. et al. Rapid Sequence Induction. World Federation of Societies of Anaesthesiologists. 2016. Wax RS, et al. Practical
recommendations for critical care and anesthesiology teams caring for novel coronavirus (2019-nCoV) patients. Can J Anesth/J Can Anesth Peng
PWH, et al. Outbreak of a new coronavirus: what anaesthetists should know.
SÃO PAULO - Secretária da Saúde do Estado de São Paulo. Orientação para o Procedimento de Emissão de Declaração de Óbito frente à
pandemia de COVID-19 no Estado de São Paulo. São Paulo, 20 Março 2020. Secretária da Saúde do Estado de São Paulo. Orientação para o
Procedimento da Declaração de Óbito. São Paulo, 20 Março 2020. - . Diário Oficial do Estado de São Paulo, Resolução SS 28 - Aprova Norma
Técnica que disciplina os serviços de necrotério, serviço de necropsia, serviço de somatoconservação de cadáveres, velório, cemitério e as
atividades de exumação, cremação e transladação, e dá outras providências. São Paulo, 25 Fev 2013. Assistência domiciliar a pacientes Suspeitos
ou confirmados e contatos - 04 de fevereiro de 2020 - Divisão de infecção hospitalar/CVE Grupo técnico médico hospitalar/sersa/cvs
Siddiqu HK, Mehra MR. COVID-19 Illness in Native and Immunosuppressed States. A Clinical-
Therapeutic Staging Proposal. Journal of Heart and Lung Transplantation, 2020; doi:
10.1016/j.healun.2020.03.012
-Fardet L, Galicier L, Lambotte O et al. Development and Validation of the HScore, a Score for
the Diagnosis of Reactive Hemophagocytic Syndrome. Arthritis Rheumatol 2014:66;2613–20.
Mario Palombo - mariopi.palombo@gmail.com - CPF: 241.468.728-20
REFERÊNCIAS
Rajter JC, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter JJ. Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With
Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study. Chest. 2021 Jan;159(1):85-92. doi: 10.1016/j.chest.2020.10.009. Epub 2020
Oct 13. PMID: 33065103; PMCID: PMC7550891.
Heidary, F., Gharebaghi, R. Ivermectina: uma revisão sistemática dos efeitos antivirais para o regime complementar COVID-19. J Antibiot 73,
593–602 (2020). https://doi.org/10.1038/s41429-020-0336-z
Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, Nigoghossian C, Ageno W, Madjid M, Guo Y, Tang LV, Hu Y, Giri J, Cushman M,
Quéré I, Dimakakos EP, Gibson CM, Lippi G, Favaloro EJ, Fareed J, Caprini JA, Tafur AJ, Burton JR, Francese DP, Wang EY, Falanga A, McLintock
C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom JW, Weinberg I, Schulman S, Carrier M, Piazza G, Beckman JA, Steg PG, Stone GW,
Rosenkranz S, Goldhaber SZ, Parikh SA, Monreal M, Krumholz HM, Konstantinides SV, Weitz JI, Lip GYH; Global COVID-19 Thrombosis
Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right
Ventricular Function. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up:
JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973. doi: 10.1016/j.jacc.2020.04.031. Epub 2020 Apr 17. PMID:
32311448; PMCID: PMC7164881.